A clinical trial can have a well-designed protocol, experienced investigators, and promising science, and still face a fundamental uncertainty: are participants taking their study medication as intended?

At AICure, we believe closing that visibility gap is essential to better clinical research. Remote medication adherence helps research teams understand dosing behavior outside the clinic, identify emerging challenges, and connect participants with timely support. Our platform combines medication reminders, AI-powered ingestion verification, and behavioral data to support adherence and patient engagement.

For clinical trial leaders, the opportunity extends beyond tracking missed doses. It is about turning adherence insights into more informed clinical oversight, more responsive patient support, and greater confidence in the evidence a study produces.

Move beyond reported adherence

A participant’s report that they took their medication is useful information. But it is not the same as evidence of the dosing event.

AICure’s smartphone-based approach adds visibility at the point of dosing. Participants receive medication reminders and dosing guidance, then use the app to record themselves taking their study medication. The platform provides dose confirmation or alerts when dosing problems are identified, helping site teams understand where follow-up may be needed.

That distinction matters because different adherence measures can tell different stories. In a Phase 2 AbbVie schizophrenia trial, pill-count adherence ranged from 97% to 100%, while drug-concentration-based adherence was 89.7% among participants monitored with AiCure and 71.9% among those monitored with modified directly observed therapy. The findings illustrate why apparent adherence and evidence of medication exposure should not be treated as interchangeable.

Remote medication adherence monitoring adds another layer of evidence, not a replacement for pharmacokinetic sampling, clinical assessment, or other protocol-required measures.

Identify adherence challenges while there is time to respond

Adherence data has limited value if it only documents a problem after the opportunity to help has passed.

AICure connects dosing information with site communication. When dosing issues are identified, site teams can follow up; participants also have access to support through the app when they have medication-related questions or concerns.

Consider a participant who begins missing scheduled doses. That pattern should prompt a conversation, not an assumption. The participant may need clarification about the dosing instructions, help using the technology, or clinical assessment of a concern affecting their willingness to continue.

Remote monitoring creates an opportunity to initiate that conversation sooner. The site team can then investigate the cause and respond appropriately within the protocol.

This is where adherence monitoring becomes more than data collection: a dosing signal leads to a patient conversation, and that conversation creates an opportunity for targeted support.

Support treatment exposure and interpret outcomes responsibly

In a 12-week randomized study involving patients with ischemic stroke receiving anticoagulation therapy, AICure reported that all participants in the intervention group had sampled drug concentrations above the study’s specified threshold, compared with half of participants in the control group.

For clinical trial leaders, these findings connect remote adherence support with an objective measure of medication exposure. They should not, however, be interpreted as proof that adherence monitoring itself improves every clinical endpoint.

An investigational therapy may or may not be effective. Improving adherence cannot make an ineffective treatment work. What it can support is a more faithful evaluation of the prescribed regimen and a clearer understanding of whether participants received treatment as intended.

Bring greater context to trial results

When clinical outcomes differ across participants, study teams need to understand more than the endpoint alone. They also need context about treatment exposure and study conduct.

AICure’s dosing data can help teams examine adherence patterns over time and identify potential issues involving participants or sites. That information can inform study management, future protocol design, and site-support strategies.

The objective is not to explain away unfavorable results or substitute adherence data for prespecified analyses. It is to reduce avoidable uncertainty around an essential question: was the treatment taken as intended?

For trial leaders, that context supports a more informed interpretation of the evidence, even when the findings do not support the investigational therapy.

Build adherence support into the trial, not around it

At AICure, we help clinical research teams understand whether the right participant takes the right medication at the right time, and turn that information into actionable insight.

For clinical trial leaders, remote patient medication adherence provides a stronger foundation for pursuing better outcomes: clearer visibility into dosing, earlier opportunities to support participants, and more informed interpretation of study results.

The greatest value comes when adherence support is built into the protocol, the participant experience, and the site-response workflow from the start, not added only after missed doses become a concern.